Загрузка...
Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
Hereditary transthyretin‐mediated (hATTR) amyloidosis is an inherited, rapidly progressive, life‐threatening disease caused by deposition of abnormal transthyretin protein. Patisiran is an RNA interference therapeutic comprising a novel, small interfering ribonucleic acid (ALN‐18328) formulated in a...
Сохранить в:
| Опубликовано в: : | J Clin Pharmacol |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6972979/ https://ncbi.nlm.nih.gov/pubmed/31322739 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1480 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|